February 28, 2015 1:12 PM ET

Life Sciences Tools and Services

Company Overview of Second Genome, Inc.

Company Overview

Second Genome, Inc., a life sciences company, develops microbiome-modulating precision therapies. Its microbiome signature discovery services include solutions for microbiome analysis, such as biological specimen storage and sample preparation; sequencing (NGS) and array-based metagenomic assays; and bioinformatics pipelines. Second Genome, Inc. was formerly known as PhyloTech, Inc. and changed its name to Second Genome, Inc. in January 2011. The company was founded in 2009 and is based in San Bruno, California.

1150 Bayhill Drive

Suite 215

San Bruno, CA 94066

United States

Founded in 2009



Key Executives for Second Genome, Inc.

Chief Executive Officer and President
Co-Founder and Chairman of the Board
Age: 57
Co-Founder and Chairperson of Scientific Advisory Board
Co-Founder and Head of Bioinformatics
Senior Vice President of Corporate Development
Age: 50
Compensation as of Fiscal Year 2014.

Second Genome, Inc. Key Developments

Second Genome, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 08:00 AM

Second Genome, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 08:00 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Karim Dabbagh, Chief Scientific Officer.

Second Genome, Inc. Presents at Life Sciences Summit 2014, Oct-29-2014 10:00 AM

Second Genome, Inc. Presents at Life Sciences Summit 2014, Oct-29-2014 10:00 AM. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle, 10th Floor, New York, NY 10019, United States. Speakers: Peter B. DiLaura, Chief Executive Officer and President.

Second Genome, Inc. and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases

Second Genome, Inc. announced that it has entered into an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer. Under the terms of the agreement, the company will identify up to eight clinical indications where the microbiome has a potential role in disease and will collaborate on microbiome research with Mayo Clinic investigators who specialize in each of the designated disease areas. Mayo Clinic will provide human clinical samples from patients in targeted disease areas, and the company will deploy its proprietary microbiome discovery platform to identify biological pathways implicated in disease. Further, the company will utilize its platform to discover novel therapies that target these microbiome-mediated pathways. Mayo Clinic will make an equity investment in the company as part of the collaboration. Financial details were not disclosed. This collaboration enables the company to access Mayo Clinic's clinical and research expertise in retrospective and prospective studies across a range of diseases. It specifically strengthens the company’s current drug discovery programs in inflammatory bowel disease and metabolic disease, while supporting the company's move into new areas such as colorectal cancer.

Similar Private Companies By Industry

Company Name Region
Covance Clinical Research Unit, Inc. United States
Hurley Consulting Associates Ltd. United States
Adesis, Inc. United States
Jasper Clinical Research & Development, Inc. United States
Swiftsure International, Inc. United States

Recent Private Companies Transactions

Private Placement
October 7, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Second Genome, Inc., please visit www.secondgenome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.